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OBJECTIVE—Hypoglycemia-associated autonomic failure
(HAAF) constitutes one of the main clinical obstacles to opti-
mum treatment of type 1 diabetes. Neurons in the ventromedial
hypothalamus are thought to mediate counterregulatory re-
sponses to hypoglycemia. We have previously hypothesized that
hypoglycemia-induced hypothalamic angiotensin might contrib-
ute to HAAF, suggesting that the angiotensin blocker valsartan
might prevent HAAF. On the other hand, clinical studies have
demonstrated that the opioid receptor blocker naloxone amelio-
rates HAAF. The goal of this study was to generate novel
hypothalamic markers of hypoglycemia and use them to assess
mechanisms mediating HAAF and its reversal.
RESEARCH DESIGN AND METHODS—Quantitative PCR
was used to validate a novel panel of hypothalamic genes
regulated by hypoglycemia. Mice were exposed to one or ﬁve
episodes of insulin-induced hypoglycemia, with or without
concurrent exposure to valsartan or naloxone. Corticosterone,
glucagon, epinephrine, and hypothalamic gene expression
were assessed after the ﬁnal episode of hypoglycemia.
RESULTS—A subset of hypothalamic genes regulated acutely
by hypoglycemia failed to respond after repetitive hypoglycemia.
Responsiveness of a subset of these genes was preserved by
naloxone but not valsartan. Notably, hypothalamic expression of
four genes, including pyruvate dehydrogenase kinase 4 and
glycerol 3-phosphate dehydrogenase 1, was acutely induced by a
single episode of hypoglycemia, but not after antecedent hypo-
glycemia; naloxone treatment prevented this failure. Similarly,
carnitine palmitoyltransferase-1 was inhibited after repetitive
hypoglycemia, and this inhibition was prevented by naloxone.
Repetitive hypoglycemia also caused a loss of hypoglycemia-
induced elevation of glucocorticoid secretion, a failure prevented
by naloxone but not valsartan.
CONCLUSIONS—Based on these observations we speculate
that acute hypoglycemia induces reprogramming of hypotha-
lamic metabolism away from glycolysis toward -oxidation,
HAAF is associated with a reversal of this reprogramming, and
naloxone preserves some responses to hypoglycemia by prevent-
ing this reversal. Diabetes 60:39–46, 2011
H
ypoglycemia-associated autonomic failure (HAAF)
is thought to constitute one of the main obsta-
cles to optimum treatment of type 1 diabetes
(1). The causes of HAAF are not known, but
counterregulatory responses appear to be mediated by
glucose-sensing neurons in the ventromedial hypothala-
mus (2–6). We have reported that acute hypoglycemia
induces hypothalamic expression of angiotensinogen (7).
Furthermore, inhibition of ACE activity appears to reduce
the risk of hypoglycemia episodes (8,9), suggesting that
angiotensin receptor blockers might prevent or even re-
verse HAAF. On the other hand, the angiotensin receptor
blocker losartan is reported to attenuate counterregula-
tory responses to hypoglycemia (10), though it is not clear
if losartan crosses the blood-brain barrier. In contrast,
clinical studies have demonstrated that naloxone im-
proves counterregulatory responses (11) and prevents
HAAF (12) in humans. In this study we therefore assessed
the effects of treatment with valsartan, an angiotensin
receptor blocker that crosses the blood-brain barrier, or
naloxone on counterregulatory and molecular responses
to hypoglycemia after antecedent hypoglycemia.
RESEARCH DESIGN AND METHODS
All studies were approved by the appropriate institutional animal review
board (Institutional Animal Care and Use Committee). Twelve-week-old male
C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME)
and housed ﬁve per cage with free access to food and water under 12:12-h
light-dark cycle (lights on at 7:00 A.M.).
Drugs. This study was designed to assess if blocking angiotensin receptors
would prevent counterregulatory failure based on our observation that
hypoglycemia induces expression of angiotensin (7). Acute inhibition of
angiotensin II production by an ACE inhibitor attenuates acute sympathetic
responses to hypoglycemia in humans (13), but speciﬁc blockade of the
angiotensin receptor A1 subtype does not block responses to hypoglycemia in
humans (14), suggesting that the AT2 receptor may mediate acute counter-
regulatory responses. Furthermore, in a wide variety of circumstances, the
AT1 receptor antagonizes effects of the AT2 receptor. For example, the AT1
receptor inhibits effects of the AT2 receptor on vasodilation (15), which is
consistent with opposing effects of these receptors in a variety of systems
(16). Furthermore, activation of the AT1 receptor increases glucose uptake
(17), suggesting that activation of the AT1 receptor would reduce sensitivity to
hypoglycemia and thus lead to counterregulatory failure. Therefore, valsartan
was chosen for the present studies because it primarily blocks AT1 receptors,
and it is the optimum protocol for oral delivery to produce protective effects
in the mouse brain without producing hypotension, which has been exhaus-
tively characterized by Wang et al. (18). We therefore administered valsartan
orally as described in that article.
Naloxone hydrochloride dihydrate (Sigma Chemical, St. Louis, MO) was
dissolved in sterile saline and injected intraperitoneally at a dose of 2 mg/kg
in a volume of 0.1 ml/10 g of body weight.
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units/kg body weight) injected intraperitoneally into mice previously fasted
for 3 h, a protocol that produced blood glucose 40 mg/dl when measured at
90 min after injection and without producing unconsciousness, seizures, or
death. We previously used a similar protocol to study hypothalamic gene
expression following hypoglycemia (7). The insulin dose was tested and
optimized prior to the experiments on age-matched C57Bl6/J mice. Blood
glucose was measured before insulin injection and after 30, 90, and 180 min
via tail prick. For antecedent hypoglycemia episodes, mice were placed in
cages without food for 3 h after the insulin injection and then moved back into
home cages with food 3 h after the insulin injection. The euglycemic
experimental group was similarly denied food access after the saline injection
concurrently with the hypoglycemia groups. On the ﬁnal day of hypoglycemia,
blood glucose was additionally measured over 240 min, at which time the
animals were killed.
Experimental design. Animals were randomly assigned to one of seven
groups (n  10), designated in Figure 1: Eu (saline-injected euglycemic), 1XH
(acute insulin-induced hypoglycemia without antecedent hypoglycemia), 5XH
(acute hypoglycemia with four antecedent days of hypoglycemia), Eu-V
(euglycemic group with oral valsartan 40 mg/kg/day), 1XH-V (acute hypogly-
cemia with oral valsartan), 5XH-V (acute hypoglycemia with four antecedent
days of hypoglycemia maintained on oral valsartan), 5XH-N (acute hypogly-
cemia with four antecedent days of hypoglycemia with 2 mg/kg naloxone
injected intraperitoneally 15 min before every insulin injection). Antecedent
hypoglycemia (5XH) consisted of four consecutive days of insulin-induced
hypoglycemia (3 h), followed on the 5th day with the ﬁnal episode of acute
hypoglycemia and the animals killed 4 h after insulin injection. The group
exposed to acute insulin–induced hypoglycemia without antecedent hypogly-
cemia (1XH) received physiological saline injections for 4 days, followed by
acute hypoglycemia on the 5th day. The euglycemic group (Eu) received
saline injections for ﬁve consecutive days. The valsartan groups (1XH-V,
5XH-V) ingested 40 mg/kg/day oral valsartan starting 5 days prior to commenc-
ing the 5-day injection protocol and continued on oral valsartan throughout
the study. Before the 40-mg/kg/day dose, the valsartan groups received a
20-mg/kg/day dose for a 2-day adjustment period. The naloxone group
(5XH-N) received an injection of naloxone (2 mg/kg, intraperitoneally) 15 min
before every insulin injection. Therefore, the 5XH-N group received a total of
5 days of insulin injections preceded on each day by an injection of naloxone.
In all cases, mice were killed 4 h after the injection of insulin (or saline for
euglycemic mice). Mice were killed following a balanced design at the start of
the light period (10:00 A.M. to 2:00 P.M.). Mice were killed by decapitation after
a brief exposure to carbon dioxide. Hypothalamic and cortical areas, along
with peripheral tissues, were quickly removed, frozen on dry ice, and stored
at 70°C until extraction of RNA. Trunk blood was collected for analysis of
corticosterone levels.
Blood chemistry. Blood chemistry was carried out in all mice (n  10, 7
groups). Blood glucose was measured by a Contour glucose meter (Bayer,
Mountain View, CA). Blood corticosterone levels were measured using an
enzyme-linked immunosorbent assay (ELISA) from Assay Designs (Ann
Arbor, MI). Blood glucagon was measured using an ELISA from Wako
Chemicals USA (Richmond, VA), and epinephrine was measured using an
ELISA from Rocky Mountain Diagnostics (Colorado Springs, CO).
Extraction of hypothalamic RNA and cDNA synthesis. Gene expression
was assessed for six mice per group based on the quality of the RNA. To
obtain the RNA for gene expression analysis by real-time RT-PCR, hypotha-
lamic tissue was homogenized in tubes containing RLT buffer (Qiagen,
Valencia, CA) supplemented with 2-ME, and total RNA was extracted using an
RNeasy Mini Kit (Qiagen). The quality of the total RNA was assessed using the
Biophotometer (Eppendorf, Hauppauge, NY). Due to the capacity limitations
of the PCR array plates, six out of ten samples from each experimental group
were selected (based on superior RNA quality) and were subjected to reverse
transcription. One g of high-quality total RNA was used for cDNA synthesis
using RT2 First Strand Kit (SABiosciences, Frederick, MD). All procedures
were performed according to the manufacturers’ protocols.
RT-PCR with custom RT
2 proﬁler PCR arrays. RT
2 Proﬁler PCR Array
(SABiosciences) technology for gene expression analysis entails a synthesis
between the proﬁling capabilities of DNA microarray and the quantitative
reliability and sensitivity of quantitative PCR (qPCR). The results are highly
reproducible within the same assay run or between different assay runs. RT
2
Proﬁler Custom PCR Arrays were used to simultaneously examine the mRNA
levels of 187 genes, including 7 housekeeping genes in 384-well plates
according to the protocol of the manufacturer (SuperArray Bioscience). The
genes were chosen based on prior DNA microarray studies as described in the
RESULTS section. The qPCR reactions were carried out using an ABI Prism 7900
thermocycler. Six of the seven housekeeping genes on the array were used to
normalize the gene expression by the Ct method. Data were analyzed using
a web-based software program provided by the manufacturer with additional
analysis using GraphPad Prism 4 for Macintosh.
Data analysis. All data are presented as mean  SEM. Statistical analysis was
performed using GraphPad Prism 4.0 by one-way ANOVA followed by Dunnett
post hoc test. P  0.05 indicates statistical signiﬁcance.
RESULTS
Novel hypothalamic hypoglycemia–induced genes. As
shown in Fig. 1, similar levels of hypoglycemia were
achieved in all insulin-injected groups.
One purpose of this study was to expand the panel of
hypothalamic genes regulated by hypoglycemia (7) to
facilitate assessing mechanisms of HAAF. Toward this
end, a series of DNA microarray studies were undertaken
to discover genes that are regulated by hypoglycemia and
fasting. From these microarrays, a set of genes was chosen
that were signiﬁcantly (by uncorrected t test) regulated in
the same direction by both hypoglycemia and fasting. The
expression of a subset of these genes was assessed in the
present study using a custom-designed qPCR array
(SABiosciences). This array is now commercially available
from SABiosciences and constitutes a powerful resource
for the scientiﬁc community. After qPCR, expression of
these genes was statistically assessed by one-way ANOVA
followed by Dunnett post hoc test. Only genes for which
the overall ANOVA was signiﬁcant (P  0.05) and an effect
FIG. 1. Blood glucose concentration throughout the study for all
experimental groups: Eu, 1XH, 5XH, Eu-V, 1XH-V, 5XH-V, 5XH-N. The
x-axis indicates the day and time points of the study (with insulin or
saline injected at time 0, and for the 5XH-N group, naloxone was
injected 15 min prior). Data are means  SE (n  10 for all groups).
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by post hoc test, which were also signiﬁcantly regulated by
fasting in a separate study, are presented in this article
(Table 1).
Hypoglycemia-induced elevation of plasma corticoste-
rone fails after antecedent hypoglycemia: prevention of
failure by naloxone, but not valsartan. In the present
study, mice were killed 4 h after insulin injection to
allow examination of hypothalamic molecular re-
sponses to gene expression (7). However, this time
point is not optimum for the assessment of the failure of
hormonal responses, which in mice are usually mea-
sured 120 min after the induction of hypoglycemia
(19,20), similar to studies in rats (4,21) and humans (22).
Thus, although we measured all three counterregulatory
hormones, any conclusions based on hormone levels at
this late time point must be interpreted with caution. As
observed in humans (23), a single acute exposure to
hypoglycemia caused a signiﬁcant elevation of plasma
corticosterone, a response completely prevented by
antecedent hypoglycemia (Fig. 2A). This counterregula-
tory failure was not prevented by treatment with valsar-
tan, but was completely prevented by treatment with
naloxone. Similarly, a single exposure to hypoglycemia
caused a signiﬁcant elevation of plasma glucagon, and
this induction was completely prevented by antecedent
hypoglycemia (Fig. 2B). Furthermore, the failure of
glucagon to respond to hypoglycemia was not rescued
by either drug treatment (Fig. 2B). Finally, plasma
epinephrine was also induced by a single episode of
hypoglycemia, but this induction was not blocked at this
time point by antecedent hypoglycemia (Fig. 2C). How-
ever, the induction appears to have been attenuated by
valsartan and naloxone (Fig. 2C). Subject to the caveat
concerning the late time point, these results do not
support that valsartan will prevent counterregulatory
failure and may in fact worsen failure. Furthermore,
naloxone, while possibly protective for activation of the
hypothalmic-adrenal-pituitary axis, may not protect
against failure in glucagon and epinephrine secretion
after antecedent hypoglycemia.
Hif3, S3-12, and GLUT1 are induced after acute and
repetitive hypoglycemia. As shown in Table 1 and Fig.
3, Hif3 (hypoxia-induced factor 3), S3-12 (perilipin
4), and GLUT1 (facilitative GLUT isoform 1) were
induced by acute hypoglycemia. Induction by hypogly-
cemia was not inﬂuenced by antecedent hypoglycemia,
valsartan, or naloxone. Thus, the induction of these
genes did not correlate with HAAF or its reversal by
naloxone. Furthermore, the induction of these genes
appears not to be dependent on hypoglycemia-induced
angiotensin since valsartan did not inﬂuence the expres-
sion of these genes. It should be noted that in this study
the induction of angiotensin by hypoglycemia did not
reach statistical signiﬁcance, so these results are not
presented here.
Induction of Pdk4, Gpd1, Angptl4,a n dCdkn1a by
acute hypoglycemia fails after antecedent hypogly-
cemia: prevention of failure by naloxone, not val-
sartan. Another set of genes was induced by acute
hypoglycemia but not after antecedent hypoglycemia:
Pdk4 (pyruvate dehydrogenase kinase 4), Gpd1 (glyc-
erol 3-phosphate dehydrogenase isoform 1), Angptl4
(also known as fasting-induced adipose factor), and
Cdkn1a (also known as p21) (Fig. 4). The failure of
these genes to respond to hypoglycemia after anteced-
ent hypoglycemia was prevented by treatment with
naloxone, but not by treatment with valsartan (Fig. 4).
Naloxone prevents the regulation of Gpd2, Cxcl14,
and Sox17 by hypoglycemia. A different pattern of
expression was observed for the genes in Fig. 5: the
regulation of these genes by hypoglycemia was not im-
paired by antecedent hypoglycemia but was prevented by
naloxone, though not by valsartan. In contrast to Gpd2
(glycerol 3-phosphate dehydrogenase isoform 2) and
Cxcl14 (chemokine [C-X-C] motif ligand14), which were
inhibited by hypoglycemia, Sox17 (SRY-box containing
gene 17) was induced by hypoglycemia.
Naloxone prevents the inhibition of Cpt1a by repet-
itive hypoglycemia. The only gene in our panel that was
signiﬁcantly regulated by repetitive hypoglycemia but not
acute hypoglycemia was Cpt1a. This inhibition was pre-
vented by naloxone (Fig. 6).
Induction of Ucp2 and Pnpla2 by acute hypoglycemia
fails after repetitive hypoglycemia, and failure is not
reversed by naloxone or valsartan. Finally, Fig. 7
depicts the genes whose induction by acute hypoglycemia
failed after antecedent hypoglycemia and whose failure
was not prevented by naloxone. These genes were Ucp2
(Uncoupling Protein 2) and Pnpla2 (also known as adi-
pose triglyceride lipase).
TABLE 1
Gene nomenclature and regulation by acute insulin–induced hypoglycemia
Gene
symbol Gene name
Reference
sequence no.
Fold change
(mean  SE) P
Angptl4 Angiopoietin-like 4 NM_020581 2.13  0.15 0.00003
Cdkn1a Cyclin-dependent kinase inhibitor 1A (p21) NM_007669 5.67  0.44 0.000001
Cpt1a Carnitine palmitoyltransferase 1a NM_013495 1.10  0.11 0.53285
Cxcl14 Chemokine (C-X-C motif) ligand 14 NM_019568 0.82  0.03 0.00133
GLUT1 facilitated glucose transporter, member 1 NM_011400 1.91  0.32 0.01853
Gpd1 Glycerol 3-phosphate dehydrogenase 1 (soluble) NM_010271 1.67  0.16 0.00708
Gpd2 Glycerol 3-phosphate dehydrogenase 2 (mitocho) NM_010274 0.94  0.01 0.03812
Hif3 Hypoxia inducible factor 3,  subunit NM_016868 2.06  0.27 0.00575
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 NM_013743 1.77  0.23 0.01009
Pnpla2 Patatin-like phospholipase domain containing 2 NM_025802 1.64  0.13 0.00084
S3-12 Perilipin 4 NM_020568 3.04  0.21 0.00007
Sox17 SRY-box containing gene 17 NM_011441 1.46  0.12 0.00565
Ucp2 Uncoupling protein 2 NM_011671 1.98  0.28 0.01186
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In these studies, we observed that 4 days of antecedent
hypoglycemia in mice completely prevented the elevation
of corticosterone produced by acute hypoglycemia (Fig.
2A) and glucagon (Fig. 2B) but not epinephrine (Fig. 2C)
when measured 240 min after the injection of insulin. The
counterregulatory failure to increase corticosterone was
prevented by naloxone, but not valsartan, and the coun-
terregulatory failure of glucagon was not prevented by
either treatment.
The pattern of gene expression in these studies suggests
a metabolic basis for HAAF and its prevention by nalox-
one. (We conclude that the effects of insulin-induced
hypoglycemia on gene expression are due to hypoglyce-
mia, not insulin, since in every case the effects of insulin-
induced hypoglycemia were in the same direction as
produced by fasting, a condition characterized by reduced
glucose and reduced insulin.) First, it should be noted that
acute hypoglycemia–induced Pdk4 (Fig. 4), which inhibits
pyruvate dehydrogenase, constitutes a classic mechanism
to shift metabolic economy away from glycolysis and
toward -oxidation (24). Such a shift would be expected to
FIG. 2. Counterregulatory hormones in mice exposed to antecedent
hypoglycemia and naloxone (2 mg/kg) or valsartan (40 mg/kg/day). Trunk
blood was collected at the time the animals were killed, 4 h after ﬁnal
insulin or saline injection. Hormone levels were measured by ELISA in the
same groups as described in Fig. 1. Data are means  SE (n  10 for all
groups). *P<0.05 as compared with the euglycemic group (Dunnett test).
FIG. 3. Real-time qPCR data for murine hypothalamic genes that do not
correlate with counterregulatory failure or its reversal by naloxone or
valsartan. Relative expression levels of (A) Hif3a,( B) S3-12, and (C)
GLUT1 were assessed using custom PCR arrays in the same groups
described in Fig. 1. Animals were killed 4 h after the ﬁnal insulin or
saline injection. Data for each gene were normalized to a panel of
housekeeping transcripts and expressed as fold change compared with
the saline-injected (euglycemic) group. Data are means  SE (n  6 for
all groups). *P < 0.05 as compared with the euglycemic group (Dunnett
test).
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metabolism. However, the induction of Pdk4 was reversed
after antecedent hypoglycemia and was prevented by
valsartan, conditions in which glucocorticoid induction
was impaired. Most important, naloxone treatment main-
tained the induction of Pdk4 by hypoglycemia in associa-
tion with the maintenance of the glucocorticoid response.
We have previously reported that estradiol, which impairs
counterregulatory responses in humans (25) and rats (26),
inhibits hypothalamic Pdk4 in association with impaired
hypothalamic responses to hypoglycemia (27). Similarly,
Jiang et al. (28) demonstrated with the use of metabolic
FIG. 4. Real-time qPCR data for murine hypothalamic genes that fail to
respond after antecedent hypoglycemia, and the failure was prevented
by naloxone, but not valsartan. Relative expression levels of (A) Pdk4,
(B) Gpd1,( C) Angptl4, and (D) Cdkn1a were assessed using custom
PCR arrays from SABiosciences in the same groups described in Fig. 1.
Animals were killed 4 h after the ﬁnal insulin or saline injection. Data
for each gene were normalized to a panel of housekeeping transcripts
and expressed as fold change compared with the saline-injected (eu-
glycemic) group. Data are means  SE (n  6 for all groups). *P < 0.05
as compared with the euglycemic group (Dunnett test).
FIG. 5. Real-time qPCR data for murine hypothalamic genes whose
regulation by hypoglycemia were not impaired by antecedent hypogly-
cemia but were prevented by naloxone, though not by valsartan.
Relative expression levels of (A) Gpd2 (glycerol 3-phosphate dehydro-
genase 2, mitochondrial), (B) Cxcl14, and (C) Sox17 were assessed
using custom PCR arrays from SABiosciences in the same groups
described in Fig. 1. Animals were killed 4 h after the ﬁnal insulin or
saline injection. Data for each gene were normalized to a panel of
housekeeping transcripts and expressed as fold change compared with
the saline-injected (euglycemic) group. Data are means  SE (n  6 for
all groups). *P < 0.05 as compared with the euglycemic group (Dunnett
test).
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robust increase in neuronal, but not glial, pyruvate dehy-
drogenase activity in association with counterregulatory
failure, consistent with a decrease in Pdk4 activity. This
set of observations suggests that HAAF is caused by a
failure to maintain the shift away from glycolysis toward
alternate fuel use in neurons, and that naloxone prevents
HAAF by maintaining this shift.
The pattern of expression of other genes supports this
metabolic shift hypothesis. For example, like Pdk4, the
induction of Angptl4 by hypoglycemia fails after anteced-
ent hypoglycemia, and this failure is prevented by nalox-
one. Angptl4 stimulates -oxidation and uncoupling (29),
directly supporting that acute hypoglycemia reprograms
hypothalamic metabolism away from glycolysis and to-
ward alternate fuel use (-oxidation), that HAAF is asso-
ciated with the failure of this reprogramming, and that
naloxone prevents HAAF by preventing this failure. Simi-
larly, hypothalamic Ucp2 has recently been shown to
mediate an induction of -oxidation (23). Similarly, repet-
itive hypoglycemia inhibited Cpt1a (Fig. 6), an effect
prevented by naloxone. -Oxidation mediated by Cpt1
constitutes a key element by which hypothalamic neurons
sense nutritional state, plausibly by reducing nutrient ﬂux
through pathways that metabolize glucose (23,30). There-
fore the reduction in -oxidation produced by repetitive
hypoglycemia would be expected to increase nutrient ﬂux
through pathways that metabolize glucose, thus increasing
sensitivity to glucose and reducing sensitivity to hypogly-
cemia. The prevention of this effect by naloxone also
supports that HAAF is caused by the failure to produce
alternative metabolic pathways to glucose utilization.
Furthermore, the induction of Gpd1 by hypoglycemia
(Fig. 4) fails after antecedent hypoglycemia, a failure
prevented by naloxone but not valsartan. Gpd1 catalyzes
the interconversion of glycerol and dihydrooxyacetone
(DHA). DHA is converted to glycerol as part of the glycerol
NADH shuttle mechanism. However, this shuttle requires
the activity of Gpd2, and in this study we observed that
hypoglycemia inhibited Gpd2 (Fig. 5), an effect that was
prevented by naloxone but not valsartan. Thus, inhibition
of the glycerol shuttle activity (which is active during
glycolysis) correlated with the failure of the counterregu-
latory elevation of corticosterone. This suggests that the
key metabolic effect of Gpd1 induction by hypoglycemia is
to catalyze conversion of glycerol to DHA, providing an
alternative to glucose for fuel; that failure in this conver-
sion is associated with counterregulatory failure; and that
naloxone prevents counterregulatory failure by maintain-
ing this alternative metabolic pathway.
The other gene most prominently implicated in HAAF
and its reversal by naloxone is Cdnk1a, more commonly
known as p21, a major inhibitor of cell division. However,
the functional signiﬁcance of Cdnk1a in counterregulation
and its failure is unclear. It is plausible that Cdnk1a
expression is a reﬂection, rather than a cause, of counter-
regulatory failure since this gene is induced by glucocor-
tiocoids (31). Interestingly, Cxc114 appears to produce
insulin resistance (32), so its inhibition by hypoglycemia
might enhance the inhibitory effect of insulin on the
counterregulatory response (33), and reversal of this inhi-
bition might mediate part of the reversal of impairments
by naloxone. Finally, Sox17 is the canonical inhibitor of
the Wnt signaling pathway (34), and some evidence sug-
gests that the Wnt pathway promotes glycolysis at the
expense of -oxidation (35). Thus, Sox17 may contribute
FIG. 7. Hypothalamic expression of genes whose induction by acute
hypoglycemia was prevented by antecedent hypoglycemia but not
maintained by exposure to naloxone. Relative expression levels of (A)
Ucp2 (uncoupling protein 2) and (B) Pnpla2 (patatin-like phospho-
lipase domain containing 2) were assessed with custom PCR arrays
from SABiosciences in the same groups described in Fig. 1. Animals
were killed 4 h after the ﬁnal insulin or saline injection. Data for each
gene were normalized to a panel of housekeeping transcripts and
expressed as fold change compared with the saline-injected (euglyce-
mic) group. Data are means  SE (n  6 for all groups). *P < 0.05 as
compared with the euglycemic group (Dunnett test).
FIG. 6. Hypothalamic expression of Cpt1a was signiﬁcantly regulated
by repetitive hypoglycemia but not acute hypoglycemia, and this
inhibition was prevented by naloxone. Relative expression level of
Cpt1a (carnitine palmitoyltransferease 1a, liver) was assessed with
custom PCR arrays from SABiosciences in the same groups described in
Fig. 1. Animals were killed 4 h after the ﬁnal insulin or saline injection.
Data for each gene were normalized to a panel of housekeeping
transcripts and expressed as fold change compared with the saline-
injected (euglycemic) group. Data are means  SE (n  6 for all
groups). *P < 0.05 as compared with the euglycemic group (Dunnett
test).
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hypoglycemia as indicated above, but since the induction
continues even after antecedent hypoglycemia, counter-
regulatory failure is probably not attributable to the
Sox17/Wnt pathway.
It should also be noted that many of the genes associ-
ated here with impaired counterregulatory elevation of
corticosterone are induced by the metabolic transcription
factor Ppar-, including Pdk4, Cpt1a, Ucp2 (36), and Gpd1
(36,37). Indeed, a major function of Ppar- is to activate
the uptake and oxidation of free fatty acids (36) and
glycerol metabolism (37). Furthermore, Ppar- knockout
exhibit hypoglycemia during fasting (38), a phenomenon
plausibly similar to HAAF. Of particular interest, whole-
body glucose use is reduced by infusing an activator of
Ppar- into the third ventricle (38). We therefore specu-
late that counterregulatory responses are enhanced by
hypothalamic activation of Ppar-, that this action fails
after repetitive hypoglycemia, that this failure is reversed
by naloxone, and that Ppar- activators such as WY13643
might also be useful in reversing counterregulatory failure.
It must be emphasized however that this speculation has
not been directly tested.
To the extent that naloxone prevented the loss of
responsiveness to hypoglycemia by antecedent hypoglyce-
mia (e.g., corticosterone, Pdk4, Angptl4, and Cdkn1a/
p21), the precise mechanism mediating these effects
remains unclear. It seems very likely that these effects of
naloxone are mediated by blockade of -opioid receptors
since these are the main known mechanisms of action of
naloxone (39). One of the most prominent responses to
hypoglycemia is the release of the natural -opioid agonist
-endorphin into the plasma from the anterior pituitary
(40). Conversely, infusion of -endorphin into the hypo-
thalamus inhibits some hypothalamic responses to hypo-
glycemia (41), which would have the effect of amplifying
glucocorticoid responses to hypoglycemia as observed in
this study. However, it remains to be determined if -en-
dorphin released from the pituitary exerts these effects in
the hypothalamus or if other sources of opioids within the
central nervous system mediate these effects.
Several major caveats apply to the present studies.
Firstly, the counterregulatory hormones were measured
240 min after insulin injection, well after the more typical
time point of around 120 min (19,20). Since those studies
demonstrated counterregulatory failure of epinephrine
after only a single antecedent exposure to hypoglycemia,
which is similar to the results in humans (42), further
analysis will be required to determine if the protocol used
in the present studies is in fact an adequate model for
human HAAF. Replicating these studies with glucose
clamps and sampling blood earlier will clarify this issue,
and the use of different doses of insulin could improve the
similarity to human HAAF. Secondly, drug levels were not
measured, so failure to produce protective effects could be
due to low drug levels in the blood. However, the doses of
valsartan were chosen based on previous doses that
produced neuroprotection without reducing blood pres-
sure (18). Thirdly, valsartan did in fact appear to impair
several responses to hypoglycemia, including glucagon
and Pdk4, suggesting that the drug was in fact having
effects at the dose used. Similarly naloxone clearly pro-
duced several effects on hormonal and molecular re-
sponses to hypoglycemia. Whether other doses would
have produced a better outcome remains to be deter-
mined. Another concern is that the magnitudes of the
effects on gene expression were rather small. However the
results were reliable because in most cases they were
observed in more than one condition, and we have cor-
roborated that fasting similarly and signiﬁcantly regulates
every gene described in this study. A more telling concern
is whether the effects observed here could functionally
account for counterregulation or its failure given the small
magnitude of the effects. With respect to this concern, we
anticipate that the most important mode of regulation of
these gene products is at the allosteric level (e.g., of Cpt1a
by malonyl-CoA) and that the regulation of expression
functions mainly as a clue to which gene products are
involved in various processes. Nevertheless, as always
with studies of gene expression, any conclusions must be
considered provisional until corroborated by more direct
assessment of function; in this case by analysis of meta-
bolic ﬂuxes.
In conclusion we describe here that naloxone, but not
valsartan, prevents counterregulatory failure after ante-
cedent hypoglycemia in mice as in humans (11,12). Pres-
ervation of counterregulatory responses was associated
with the preservation of responsiveness to hypoglycemia
of a subset of hypoglycemia-regulated genes reported here
for the ﬁrst time. The pattern of responses of these genes
in relation to counterregulatory failure and its prevention
by naloxone suggests that naloxone preserves counter-
regulatory responses by maintaining a metabolic proﬁle in
which alternate fuels are used instead of glucose. Never-
theless, since this study did not include groups in which
naloxone was only given once or not on the last day, it
remains to be determined if the effect of naloxone was to
prevent the failure of hypoglycemia-induced responses or
to directly induce corticostereone secretion and related
changes in hypothalamic gene expression. In contrast,
valsartan did not prevent or reverse loss of responsiveness
to hypoglycemia of these genes. Nevertheless, the dose of
valsartan used is neuroprotective (18) and did block some
responses to hypoglycemia, suggesting that the hypothesis
that elevated angiotensin produces HAAF is probably
incorrect. Further analysis with mice in which either the
AT1 or the AT2 receptor has been ablated may clarify this
issue. Taken together, these studies suggest that manipu-
lations causing reprogramming of hypothalamic metabolic
processes away from glycolysis and toward alternate fuel
use might be useful in preventing or reversing HAAF.
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